Loading
Cancer centre of the University of Cincinnati and UC Health, where John Byrd, who led the ibrutinib trials in chronic lymphocytic leukaemia, chairs the Department of Internal Medicine.
The University of Cincinnati Cancer Center is the joint cancer centre of the University of Cincinnati College of Medicine, UC Health and Cincinnati Children's Hospital. John Byrd, whose trials at Ohio State established ibrutinib and then acalabrutinib in chronic lymphocytic leukaemia, moved to Cincinnati in 2021 as chair of the Department of Internal Medicine and leads its leukaemia research programme.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to University of Cincinnati, including child institutions. 477 works · 3,951 citations · 62% open access · 11% clinical trials · 3% reviews.